Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct;98(4):539-560.
doi: 10.1111/cbdd.13909. Epub 2021 Jul 4.

Alpha-amylase as molecular target for treatment of diabetes mellitus: A comprehensive review

Navjot Kaur  1 , Vanktesh Kumar  1 , Surendra Kumar Nayak  1 , Pankaj Wadhwa  1 , Paranjit Kaur  1 , Sanjeev Kumar Sahu  1
Affiliations
Review

Alpha-amylase as molecular target for treatment of diabetes mellitus: A comprehensive review

Navjot Kaur et al. Chem Biol Drug Des. 2021 Oct.

Abstract

The alpha (α)-amylase is a calcium metalloenzyme that aids digestion by breaking down polysaccharide molecules into smaller ones such as glucose and maltose. In addition, the enzyme causes postprandial hyperglycaemia and blood glucose levels to rise. α-Amylase is a well-known therapeutic target for the treatment and maintenance of postprandial blood glucose elevations. Various enzymatic inhibitors, such as acarbose, miglitol and voglibose, have been found to be effective in targeting this enzyme, prompting researchers to express an interest in developing potent alpha-amylase inhibitor molecules. The review mainly focused on designing different derivatives of drug molecules such as benzofuran hydrazone, indole hydrazone, spiroindolone, benzotriazoles, 1,3-diaryl-3-(arylamino) propan-1-one, oxadiazole and flavonoids along with their target-receptor interactions, IC50 values and other biological activities.

Keywords: alpha-amylase; alpha-amylase inhibitors; antidiabetic drug; diabetes mellitus; molecular target.

PubMed Disclaimer

References

REFERENCES

    1. Agarwal, P. (2016). Alpha-amylase inhibition can treat diabetes mellitus. Research and Reviews Journal of Medical and Health Sciences, 5(4), 1-8.
    1. Agarwal, P., & Gupta, R. (2016). Alpha-amylase inhibition can treat diabetes mellitus. Research and Reviews: Journal of Medical Health Sciences, 5(4), 1-8.
    1. Aispuro-Pérez, A., López-Ávalos, J., García-Páez, F., Montes-Avila, J., Picos-Corrales, L. A., Ochoa-Terán, A., Bastidas, P., Montaño, S., Calderón-Zamora, L., Osuna-Martínez, U., & Sarmiento-Sánchez, J. I. (2020). Synthesis and molecular docking studies of imines as α-glucosidase and α-amylase inhibitors. Bioorganic Chemistry, 94, 103491. https://doi.org/10.1016/j.bioorg.2019.103491
    1. Altowyan, M. S., Barakat, A., Al-Majid, A. M., & Al-Ghulikah, H. (2019). Spiroindolone analogues as potential hypoglycemic with dual inhibitory activity on α-amylase and α-glucosidase. Molecules, 24(12), 2342.-https://doi.org/10.3390/molecules24122342
    1. Andel, M. (2001). Diabetology at the threshold of the 21st century. Vnitrni Lekarstvi, 47(5), 277-280.

MeSH terms

LinkOut - more resources